Pulmonary infiltrates frequently complicate hematopoietic SCT (HSCT). The utility of fiberoptic bronchoscopy (FOB) with bronchoalveolar lavage (BAL) in the evaluation of new pulmonary infiltrates, particularly as it relates to optimal timing of the procedure, is unclear. Based on this, we retrospectively reviewed 501 consecutive, adult, nonintubated patients who underwent 598 BALs for evaluation of new pulmonary infiltrates during the first 100 days following HSCT to determine whether diagnostic yields for infection, subsequent antimicrobial treatment modifications and patient outcomes differed following early vs late referrals for the procedure. The overall yield of BAL for clinically significant pathogens was 55%. Notably, the yield was 2.5-fold higher among FOBs performed within the first 4 days of presentation (early FOB) compared to those performed late, and highest (75%) when performed within 24 h of clinical presentation. Rates of FOB-guided adjustments in antimicrobial therapy (51%) did not differ significantly between early and late examinations. However, late FOB-related antibiotic adjustments were associated with 30-day pulmonary-associated deaths that were threefold higher (6 vs 18%, P ¼ 0.0351). Major FOB-related complications occurred in only three (0.6%) patients. We conclude that early referral for FOB in this patient setting is associated with higher diagnostic yields and may favorably impact survival.
Introduction
Opportunistic infections are common sequelae of intense peri-or post transplant immunosuppression associated with conditioning regimens following HSCT. Pneumonia, the most common infectious complication in this patient population, must be distinguished from noninfectious lung conditions such as bronchiolitis obliterans with organizing pneumonia, diffuse alveolar hemorrhage (DAH) and engraftment syndrome. Such distinction is frequently difficult, obscured by overlapping signs and symptoms, and resulting in delayed and often inappropriate therapy.
Early recognition and treatment of pneumonia in the post transplant setting favorably impacts survival. [1] [2] [3] Bronchoalveolar lavage (BAL) has been widely used in the evaluation of new pulmonary infiltrates in the post transplant setting. However its diagnostic utility, particularly as it relates to the timing of the procedure, has not been established. Patients are often referred for fiberoptic bronchoscopy (FOB) after persistence of symptoms and/or radiologic evidence of progression of infiltrates several days after empiric antimicrobial therapy has been initiated. Yet, empiric antimicrobial regimens have been reported to provide inadequate coverage in up to 42% of patients with microbiologically documented pneumonias that were later determined at FOB. 4, 5 Moreover, prolonged empiric therapy may suppress the growth of pathogens, resulting in increased rates of nondiagnostic FOBs. 4 Finally, the delayed use of effective antimicrobial agents has been linked to the emergence of resistant organisms and poor outcomes, including increased in-hospital mortality. [6] [7] [8] The diagnostic yield of FOB in the immunocompromised host is variable (31-80%), and consensus regarding its utility in guiding therapeutic decisions and influencing outcomes-even when a likely pathogen is recovered-is lacking. 5, [9] [10] [11] [12] [13] [14] [15] [16] Additionally, FOB-related complication rates in the post transplant setting exceeding 20% in some studies have increased skepticism for this procedure. 1, 17 We hypothesized that the low diagnostic yields of post transplant FOB correlate with the duration of previous empiric antimicrobial therapy and delays in referrals for the procedure. In this retrospective study, we reviewed our extensive experience with FOB following HSCT at MD Anderson Cancer Center and studied the impact of FOB timing relative to clinical presentation on the yield of this procedure. The safety of the procedure, its utility in guiding modifications in pharmacologic therapy and whether subsequent treatment modifications impacted survival were also reviewed.
Methods

Patient population
The study included nonintubated adult patients (inpatients or outpatients) at MD Anderson Cancer Center who underwent FOB with BAL between January 1994 and December 1999 for the evaluation of new pulmonary infiltrates occurring within the first 100 days following HSCT. Data were extracted from a computerized database and chart review. Demographic and clinical data including age, gender, race, cancer diagnosis, pretransplant conditioning regimen, type of transplant (autologous, allogeneic, syngeneic), donor relation (related or unrelated), HLAcompatibility (matched or mismatched) and stem cell source (BM, peripheral blood, cord blood) were analyzed.
Recorded variables
Specific pulmonary complications were analyzed and categorized into infectious and noninfectious etiologies. The time interval between HSCT and the development of pulmonary infiltrates seen on chest radiographs (CXR) was recorded. Time to FOB was designated by the interval between the detection of pulmonary infiltrates and performance of FOB. This interval was categorized according to studies published earlier 2 as less than or equal to 4 days (defined as early FOB), or greater than or equal to 5 days (defined as late FOB). Among patients who underwent multiple FOBs, each procedure was recorded and considered independently. Other variables included the type and duration of antibiotic therapy before FOB; therapeutic changes that occurred as a result of FOB findings; the presence of GVHD; patterns of infiltrates on CXR (focal, multifocal or diffuse interstitial or alveolar infiltrates); oxygen requirements before FOB; ANC and platelet counts at the time of the procedure. Empiric anti-infective therapy was deemed inadequate when it failed to provide coverage of pathogens recovered from FOB. FOB-guided changes in patient management were defined as any addition or withdrawal of anti-infective therapy resulting from FOB findings. Withdrawal of anti-infective therapy within 48 h of a nondiagnostic procedure also constituted a FOBguided change in patient management. Causes of death following transplantation were recorded and grouped into primary pulmonary and nonpulmonary etiologies. Progression of infiltrates resulting in respiratory failure and death within 30 days and 100 days following FOB was recorded as pulmonary-associated mortality.
Transplant procedure
Patients received chemotherapy with or without TBI or involved site radiation tailored to the treatment of the specific underlying disease. Antibiotic prophylaxis was given after HSCT as per standard protocols. Antimicrobial prophylaxis for Gram-negative rods (Ciprofloxicin) was started at the time of transplant and continued through the time of engraftment. Empiric coverage for Pneumocystis jirovecii pneumonia was given as trimethoprim (160 mg)/ sulfamethoxazole (800 mg) twice a day for 5-7 days before the transplant and again after engraftment. Patients intolerant of sulfa drugs received pentamidine, 300 mg, administered i.v. or by nebulized therapy every 3-4 weeks. Fluconazole, at a dose of 200 mg daily, was typically administered 2 days before transplantation and continued through the time of engraftment. Patients with new fever or respiratory symptoms routinely underwent CXR and cultures of sputum and blood. Empiric antibacterial therapy consisted of a broad-spectrum i.v. b-lactam with or without i.v. vancomycin. Amphotericin B-based empiric antifungal therapy was reserved for those patients with prolonged neutropenia and fever despite 3-5 days of broadspectrum antibiotic coverage.
Bronchoscopic evaluation. FOB was typically performed within 24 h of the pulmonary consultation and at the discretion of the consulting pulmonologist. The decision to proceed with FOB was based on the assessment of the relative risks/benefits of the procedure. In general, FOB was avoided in patients whose assessment suggested that the procedure would further compromise an already tenuous hemodynamic and/or respiratory status. Hence, patients underwent FOB only if their oxygen saturation exceeded 90% on room air or on supplemental oxygen. BAL was performed on patients with all levels of thrombocytopenia. Other diagnostic techniques included Gram stains and cultures of samples of spontaneous or induced sputum, blood cultures, CMV antigenemia and nasal washings for viral antigen detection and culture.
FOB was performed after an 8-h fast using conscious sedation according to established protocols. 18, 19 Bronchi were inspected to the subsegmental level. Samples were collected during BAL by instillation of 120 ml of normal saline given in 20 ml aliquots with gentle aspiration of fluid after each aliquot. The aspirates were pooled for microbiologic and cytologic analyses. Transbronchial biopsies (TBBx) were performed with BAL if the platelet count was greater than 80 Â 106/ml and at the discretion of the pulmonologist. Biopsies were obtained under fluoroscopic guidance by passing forceps through the working channel of the bronchoscope. Two to six passes (mean ¼ 3) were obtained per examination. BALs and TBBx were performed in lung subsegments that corresponded to areas of radiographic abnormalities.
Diagnostic criteria BAL fluid and tissue samples were promptly submitted for routine cytopathologic analysis and microbiological cultures (bacterial, fungal, mycobacterial, viral). Direct fluorescein antibody for Legionella, stains for acid-fast bacilli and special stains for fungi and Pneumocystis were used. The diagnosis of pneumonia was established based on ATS guidelines. 3 Specifically, bacterial organisms were considered pathogens when at least two of the following criteria were present: (1) strong clinical suspicion for lower respiratory tract infection (presence of fever, cough, purulent sputum, pleurisy or leukocytosis); (2) cytocentrifuge preparations of BAL fluid containing 42% intracellular bacteria and (3) blood culture results yielding the same organism as that recovered from BAL fluid. The diagnosis of CMV pneumonia was based on the identification of intranuclear or intracytoplasmic inclusion bodies in addition to positive culture results and/or positive stains for CMV-specific antigens by direct immunofluorescence assays. Fungal pneumonia was identified using standardized concensus criteria (European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the Mycosis Study Group. 4 Staining for Pneumocystis jirovicii, or isolation of Mycobacterium tuberculosis, respiratory syncytial virus or influenza virus from BAL fluid was sufficient for diagnosis of pneumonia. Polymicrobial pneumonias were defined as the recovery of more than one pathogen (multiple bacterial, fungal, viral or mixed isolates) within a single BAL sample. DAH was diagnosed by the presence of progressively bloody aliquots of sequential samples of recovered lavage fluid. The presence and intensity of hemorrhage was also determined by assessment of the hemosiderin content of alveolar macrophages on all BAL samples.
Assessment of severity of pulmonary disease. Clinical parameters, including oxygen requirements, estimates of blood oxygenation, pattern of radiographic abnormality (focal, multifocal, diffuse), Eastern Cooperative Oncology Group (ECOG) score and associated comorbid conditions were used to assess disease severity. Oxygen requirements were normalized using the ratio of arterial oxygen saturation (SaO2) to inspired oxygen (FIO2). For patients requiring supplemental oxygen at the time of the procedure, each liter of supplemental oxygen was multiplied by a factor of 0.02 and added to the room air FIO2. Higher scores were associated with less respiratory impairment. Thus, a patient breathing room air with an observed SaO2 of 98% would have a SaO2/FIO2 ratio of 4.66 (0.98/0.21) whereas a patient requiring 5 l of oxygen with an SaO2 of 90% would have a ratio of 2.90 (0.90/0.02 Â 5 þ 0.21). Recorded comorbid conditions included hypotension (systolic BP o90), cardiac disease, preexisting restrictive or obstructive lung disease, diabetes, sepsis, altered mental status, liver disease (aspartate aminotransferase 440 U/l, alanine aminotransferase 456 U/l), renal disease (creatinine42 mg/100 ml) and severe anemia (hematocrit o21%).
FOB-related complications: major vs minor. Reported complications were sorted according to major and minor criteria. FOB was considered causative if the adverse event occurred during or within 24 h following the procedure. Minor complications included transient hypotension during the procedure that did not require additional therapy, mild desaturation requiring additional supplemental oxygen only during the procedure, self-limited alveolar or endobronchial bleeding, nonsustained arrhythmias of no hemodynamic consequence and bronchospasm or stridor that resolved with discontinuation of the procedure. Pneumothorax, the need for vasopressor support during or following the procedure, and postprocedure increased FIO2 requirements were defined as major complications. Untoward events requiring admission of an outpatient to an inpatient unit or the need for intensive care unit monitoring, mechanical ventilation and death within 24 h following FOB were also considered major complications.
Statistical analysis
Descriptive statistics were used to summarize the patients' demographic characteristics, comorbidities and outcomes, including diagnostic yields. w 2 -Test was used to examine the association of categorical variables. Logistic regression model was used to select variables that have significant effects on a binary outcome (infection 'Yes' or 'No'). A P-value less than 0.05 was considered significant. All statistical analysis was performed in SAS Version 9.1 (SAS Institute, Cary, NC, USA).
Results
Patient population
Of the 2181 patients transplanted between 1 January 1994 and 31 December 1999, 674 (31%) developed respiratory symptoms and new radiographic abnormalities during the first 100 days following HSCT. Among these 674, most patients (598; 88%) underwent FOB with BAL (Table 1) . In 61 of the 76 remaining patients (80%), with clinical suspicion of pneumonia who did not undergo FOB, antimicrobial therapy was initiated, based on positive sputum and/or blood cultures, and thus pulmonary consultation for FOB was not requested. The remaining 15 patients were referred for pulmonary consultation, but did not undergo FOB either because of patient refusal or concerns regarding patient safety. Only 11% of patients underwent TBBx at the time of BAL. Rates of TBBx were evenly distributed among early and late FOBs (10% of early exams, 12% of late exams, P ¼ 0.9710). FOBs were performed throughout the year. No seasonal variability in the rates of early vs late FOB examinations was observed.
Fifty-eight percent of the BALs were performed early (o4 days). Patient demographics, including age, race, gender, underlying malignancy, transplant allotypes, HLA histocompatibility and donor cell source were similarly distributed among the early and late FOB groups. Allogeneic transplants were nearly twice as likely to undergo FOB as compared to their autologous counterparts. This observation held true among both early and late FOB studies. The interval between HSCT and new infiltrates (median 19 days, range 1-98 days) did not differ significantly between early and late FOB groups or transplant type. All patients underwent a CXR at presentation. Chest computed tomography (CT) evaluations were included in the diagnostic evaluation in only 37% of patients before FOB and were more often performed among the late FOB group (55 vs 27%, P ¼ 0.024). No significant difference in the incidence of focal and diffuse disease was noted among early vs late FOB examinations (P ¼ 0.882). At the time of FOB, 32% of autologous and 53% of allogeneic transplant recipients were neutropenic, defined as an ANC less than 1000 cells/ml blood. Rates of neutropenia were higher among early FOBs compared to late examinations for both allogeneic and autologous transplant recipients, although these differences only reached statistical significance among the allogeneic transplant group. Normalized oxygen scores were higher among late FOBs (3.63 vs 3.42, Po0.007), indicating less respiratory impairment at the time of the procedure among this group of patients. No significant difference in ECOG scores and rates of GVHD was identified between the early and late FOB patient groups.
Ninety-eight percent of patients who underwent early FOB and all patients who underwent late exams were receiving empiric broad-spectrum antibiotics at the time of the examination. All empiric antimicrobial regimens offered broad Gram-positive and Gram-negative coverage. However, rates of empiric antiviral and antifungal coverage at FOB varied with the timing of the procedure. Among early FOBs, 23% of patients were receiving antiviral therapy and 27% antifungal agents before the procedure. Antiviral and antifungal therapies among late FOB recipients were much higher, 56 and 87%, respectively. The median time between initiation of empiric antibiotic therapy and FOB for the early and late FOB groups were 1.9 days and 6.2 days, respectively.
BAL was successful in identifying clinically significant pathogens in 55% of patients. Early FOBs were more than twice as likely to yield a diagnosis of infection compared to late examinations (73 vs 31%, Po0.0001). The diagnosis of infection was highest when FOBs were performed within 24 h of presentation (75%). At 5 days following presentation, the yield of infection declined to 40%, and at 10 or more days, less than 14% of patients had culture-positive examinations. DAH represented the major noninfectious diagnosis, with an overall incidence of 7%. DAH was (Table 2) . Severe neutropenia (ANC o100) appeared to have the greatest negative impact on diagnostic yield with an overall yield of only 32%. Among the 19 patients with severe neutropenia and late FOB, only 1 isolate was found (5%) compared to 10 of the 22 (45%) early examinations. Rates of bacterial, viral and polymicrobial isolates were roughly similar among autologous and allogeneic transplant groups (Table 3a and b) . Excess fungal pneumonias, however, occurred at rates nearly 2.5-fold higher among allogeneic transplant recipients compared to their autologous counterparts (24% of allogeneic transplants vs 10% of autologous recipients). The spectrum and sensitivity of microbial isolates also varied with FOB timing. Although pansensitive, single isolate bacterial organisms were the most common category of infection among both transplant groups, rates of polymicrobial and multidrug-resistant (MDR) bacterial pathogens were detected at significantly higher rates among late FOB examinations. For example, compared to early FOBs, MDR isolates of late exams were detected at rates that were eightfold higher (27 vs 3%, Po0.0001) among autologous transplant recipients and fivefold higher among recipients of allogeneic transplants (20 vs 4%, Po0.0001). Specific MDR bacterial isolates included MDR Pseudomonas aeruginosa, Stenotrophomonas maltophilia and methicillin-resistant Staphylococcus aureus. In addition, in contrast to pansensitive Aspergillus fumigatus, which was recovered from both early and late bronchoscopic examinations, resistant A. terreus was only isolated from the late exams.
Among the 58 viral pneumonias, nearly half (28) were caused by CMV, which was more often recovered from early FOB evaluations (22 of 28, 78%). Rates of recovery of CMV were similar among autologous and allogeneic transplant recipients (13 of 28 (46%) vs 15 of 28 (54%), respectively). Other viral pathogens, including adenovirus, influenza A, parainfluenza virus and respiratory syncytial virus were isolated in smaller numbers among early and late FOB examinations and distributed roughly evenly among both transplant groups. Fungal species represented nearly 20% of all pathogens identified. Aspergillus species was the major fungal pulmonary pathogen (70% of all fungal isolates) and the major cause of fatal fungal pneumonias (71% of all fatal fungal pneumonias at 30 days) regardless of transplant type or bronchoscopic timing.
Analysis of tissue samples correlated with isolates on BAL in 21 of the 65 patients (32%) who underwent combined BAL/TBBx. TBBx was positive for infection in the setting of negative BAL results in 5 patients (Gramnegative rod ¼ 1, CMV ¼ 3, HSV ¼ 1). All these five patients underwent early FOBs. Alveolar hemorrhage was confirmed in 3 patients with TBBx, and findings in an additional 36 patients (54%) only yielded nonspecific inflammation with or without fibrosis.
Significantly lower mortality rates for both the 30-and 100-day time periods were observed when a diagnosis of infection was confirmed by early FOB compared to late examinations ( Figure 1 ). For example, the 30-day pulmonary mortality among patients with a positive diagnosis of infection was 6% compared to 14% among late FOBs 
The most frequent infectious diagnoses leading to death were fungal, polymicrobial and MDR pneumonias. Together, these pneumonias accounted for 53% of fatal pneumonias at 30 days and were more commonly encountered in the late FOB group (64 vs 24%, P ¼ 0.0004). These pathogens were also the most frequent cause of all fatal pneumonias at 100 days following FOB, accounting for 57% of deaths in this group of patients. Fatal pneumonias owing to these organisms were similarly overrepresented in the late FOB group (43% late FOB vs 17% early exams, Po0.002). Lower pulmonary mortality rates at 30 and 100 days were observed among culturenegative, early FOBs compared to culture-negative, late exams. Pulmonary mortality rates among early FOBs in this category were 2% compared to 22% among late exams at 30 days and 12% compared to 45% at 100 days.
FOB-guided changes in therapy and impact on outcome FOB-guided alterations in antibiotic management occurred among approximately 51% of patients in whom pneumonia was documented. Rates of FOB-guided changes were similar among the early and late FOB groups (50 vs 51%). Pathogen identification prompted withdrawal of inappropriate initial antibiotic therapy as the sole therapeutic maneuver in 60% of early FOBs but only 15% of late exams. In the later, withdrawal of inappropriate therapy typically occurred in conjunction with the addition of alternative antimicrobial agents and/or steroids. Withdrawal of inappropriate antibiotics as the single therapeutic maneuver was also more often seen among culture-negative early FOBs compared to late exams (85 vs 23%, Po0.0001). The therapeutic approach to culture-negative late FOB examinations more often involved the addition of steroid therapy and other antimicrobial agents without discontinuation of previous drug therapy.
Delays in the FOB examinations influenced the efficacy of subsequent therapeutic modifications (Table 4) . For example, changes in antibiotic regimens that were made in accordance with culture-positive results of early FOB were associated with 6% pulmonary mortality rate at 30 days. When treatment modifications were rendered based on culturepositive late examinations, 30-day mortality rates were much higher (18%, P ¼ 0.0351). Pulmonary mortality rates among patients with FOB-guided treatment changes based on culture-negative examinations were higher than those in which a pathogen was identified. Treatment changes that were guided by culture-negative, late FOBs were associated with the highest mortality rates, regardless of modifications in therapy. Mortality rates were lowest when sensitivity testing following early FOB suggested appropriate prebronchoscopy empiric antimicrobial choices and no need for a change in therapy. For example, none of the patients with culture-positive early FOBs in which sensitivity analyses confirmed appropriate empiric antimicrobial therapy died within 30 days following the procedure compared to 6% of patients in which a specific diagnosis prompted adjustments in therapy.
Bronchoscopic complications
Adverse events were reported in 74 of the 598 (12.3%) FOB examinations, of which only 3 (0.6%) were considered major. No procedure-related death was encountered. All the three patients with major complications required high inspired oxygen (FIO2460%) at the time of the initial pulmonary evaluation and FOB. Patients with significant thrombocytopenia (plts counts less than 20 000) more frequently had increased recovery of blood from the lavage fluid, although there was no increased incidence of procedure-related bleeding within the airways of this group of patients.
Discussion
The wide variation in reported yields of FOB has been attributed to heterogeneity of patient populations, mean time intervals between transplantation and FOB, severity of illness and the manner in which the diagnostic yield is estimated. 1 Bronchoscopic techniques, including volume of . Significantly lower mortality rates were observed when a diagnosis of infection was confirmed by early fiberoptic bronchoscopy (FOB; black bars) compared to late examinations (checkered bars). Early culture-negative FOBs were also associated with lower mortality rates compared to late culture-negative exams. These findings were true for both 30-and 100-day mortality rates. Abbreviation: FOB ¼ fiberoptic bronchoscopy.
Utility of FOB following HSCT VR Shannon et al lavage fluid instilled and method of fluid recovery are not standardized at most institutions and thus wide variations in bronchoscopic methods likely add to inter-and intrainstitutional differences in reported FOB outcomes. 1, 9, 10, 13, 15, 16, 20 Our study suggests that the timing of FOB is another critical factor and that the yield of the procedure wanes with elapsed time following clinical presentation. Our overall yield of 55% is notable in light of the near universal administration of antimicrobial therapy following HSCT, which may diminish the sensitivity and specificity of bronchoscopically obtained cultures. 12, 17, 21 We found that early FOBs were 2.5 times more likely to establish a diagnosis of pneumonia compared to late examinations (Po0.0001). Furthermore, early and late FOBs differed qualitatively in terms of responsible pathogens and resistance characteristics. Late examinations were more often associated with recovery of multiresistant and polymicrobial infections and the highest 30-and 100-day pulmonary mortality rates. The higher mortality following late FOB was seen across all categories of infection and occurred regardless of adjustments in antibiotic therapy.
Less than 40% of patients in our study had CT evaluations before undergoing FOB. Over the past decade the superiority of chest CT imaging studies to plain CXR in the detection and characterization of lung disease has been well documented 22 and CT imaging is now used as an early tool in the initial assessment of immunocompromised patients with unexplained pulmonary infiltrates. In addition, by allowing site-directed FOB examinations, chest CT imaging has been shown to improve diagnostic yields of bronchoscopic studies. 23 Thus, the changing role of chest CT imaging coupled with advancements in cytologic and microbiologic detection methods over the past decade should further augment the utility of FOB in evaluating this group of patients. Factors identified as predictive of lower diagnostic yields of FOB in previous studies include the presence of GVHD, neutropenia and radiographic evidence of diffuse infiltrates (as opposed to localized infiltrates or focal masses and nodules). 24, 25 Our findings extend these observations. Yields were lowest among patients with GVHD, neutropenia or diffuse infiltrates, however, within each of these patient categories, rates of FOB-positive isolates were 2-to 4-fold higher among early FOBs compared to late exams.
TBBx correlated with the BAL diagnosis of infection in approximately one-third of patients, but provided an additional diagnosis of infection in only five patients. The limited benefit of TBBx in augmenting the yield of infectious diagnoses in our study is at variance with other reports. For example, Cazzadori et al. 26 reported that the addition of TBBx to BAL in immunocompromised patients afforded a 33% increase in the diagnostic yield of infection over BAL alone. In another study of immunocompromised patients with unexplained pulmonary infiltrates, a 64% diagnostic yield of TBBx was reported. 12 HSCT recipients comprised a minority of the patients in each of these studies, which likely impacts their findings. Nondiagnostic FOBs in our study prompted evaluation for open lung biopsy in a small number (7%) of patients. Surgical biopsies occurred 4-9 days after FOB and revealed specific diagnoses in 6 patients (bronchiolitis obliterans, n ¼ 3; malignancy, n ¼ 1; histopathologic confirmation of CMV, n ¼ 2) with the remaining studies positive only for nonspecific inflammation with or without fibrosis (data not shown). Although our numbers are small, the frequent finding of a nonspecific lung injury pattern on lung biopsy specimens, particularly in the setting of neutropenia and HSCT is consistent with other studies. 15 The lack of influence of FOB-guided treatment changes on mortality among late FOBs is consistent with reports in the literature. 25, 27 However, in previous investigations the timing of FOB relative to clinical presentation has not been consistently documented. When reported, FOB typically occurred 4 or more days following the initiation of empiric antibiotics. 11, 12, 25, 27, 28 Thus, our findings corroborate previous observations that link diagnostic delays to poor patient outcome and underscore the futility of late FOBguided antimicrobial adjustments in offsetting mortality among HSCT recipients with suspected pneumonia. A notable difference in our study compared with previousreports, however, is the significantly lower mortality rate associated with antibiotic modifications following early FOB. The threefold decrease in mortality rates among this group of patients in our study suggests that treatment adjustments when performed early may, in fact, favorably impact survival. This observation is at variance with previous reports and likely is explained by bronchoscopic timing, a factor that has not been evaluated in other studies.
Late FOB excess mortality was observed despite a tendency toward a higher ANC and significantly higher normalized oxygen scores, suggesting less respiratory impairment among the late exam group at FOB. Excess mortality among late FOB recipients may be explained, in part, by increased incidence of polymicrobial infections and the emergence of more resistant pathogens during drug selection pressure. Late FOB recipients were more often exposed to longer periods of multiagent empiric antimicrobial therapy before FOB. In addition, therapeutic modifications following late examinations more often involved the addition of new antibiotics after prolonged exposure to preexisting inappropriate ones. Delays in initiation of appropriate therapy as well as prolonged exposure to potentially toxic medications may have added to the higher rates of demise among this group of patients. Interestingly, mortality rates were highest in our study when sensitivity testing documented inappropriate prebronchoscopy antimicrobial choices, indicating a need for change in therapy. This finding is supported by several studies in which inappropriate initial empiric antimicrobial choices were associated with increased morbidity, length of hospital stay and mortality. 6, 29 Other confounding factors that have been shown to be predictive of increased mortality in the HSCT setting, including ECOG scores, neutropenia, GVHD and degree of radiographic abnormalities did not reach statistical significance between the two groups of patients in our study. Similarly, demographic factors such as race, age, gender, underlying cancer diagnosis, stem cell source, transplant allotype were also statistically similar between the early and late exam groups.
The 7% incidence of DAH in our observation is consistent with the reported incidence of 1-20% in the literature. 1, 30, 31 Rates exceeding 35% have also been reported, particularly in the setting of acute respiratory failure and infection-associated DAH.
9,32 DAH was identified more often among early FOBs in our study. Differences in the rates of airway blood absorption and the formation and clearance of hemosiderin-laden airway macrophages as a function of time may, in part, explain the disparities in the rates of detection of DAH following early vs late FOB. 33, 34 FOB-related complications, including bleeding, bradycardia, bronchospasm, hypoxia and cardiopulmonary arrest, have been published, with rates ranging from 20-27%. [1] [2] [3] [4] [5] 11, 35 Our overall incidence of FOB-related complications of 12% is lower than that reported in the literature. Moreover, major complications occurred in only three patients (0.6%), despite the high acuity of illness in our patient population.
Our investigation represents the largest series of patients who underwent FOB for suspected pneumonia following HSCT. Limitations of our study, including the inherent flaws of this retrospective investigation, however, should be acknowledged. In addition, selection bias, based on the referral patterns for FOB by the attending clinicians may have skewed the data. Our study does not represent the incidence of pneumonia following HSCT, as this would require analysis of all HSCT patients with new pulmonary infiltrates. As the study was carried out at a single institution, the results may not be applicable to other centers with different antibiotic prophylaxis and treatment practices and, therefore, different epidemiology and resistance patterns of pathogens. In addition, the spectrum of infections and resistance patterns in the HSCT population has changed over the past decade, owing to the emergence of new antimicrobials, and changes in transplant protocols and preemptive strategies against infection. Therefore, the incidence of specific infections in the post-HSCT setting has likely changed since these data were collected. Nonetheless, pneumonia remains a leading cause of death following HSCT and thus, our findings, which document the impact of FOB timing on diagnostic yield and mortality following HSCT remain highly relevant. Finally, our study does not prove a causal relationship between delayed diagnosis of infection and increased mortality, but does offer strong support to previous observations regarding this subject.
In summary, our study suggests that delays in bronchoscopic evaluation of new pulmonary infiltrates following HSCT compromise the diagnostic yield, influence the adequacy of initial therapy and impact mortality. We therefore recommend that FOB be used as a key component of the upfront diagnostic evaluation of patients with new pulmonary infiltrates following HSCT and not reserved as part of a backup strategy for patients who fail initial empiric therapy. Future prospective studies of early vs late FOB in HSCT are needed to confirm these findings.
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